Prothena (PRTA) Potential Parkinson's Treatment, Envivio (ENVI) Improved Results, Nike (NKE) …

Prothena Corporation plc (PRTA)

Prothena Corporation plc (PRTA)said that results from a Phase 1 single ascending dose study showed that administration of PRX002, a monoclonal antibody for the potential treatment of Parkinson`s disease and other related synucleinopathies, leads to mean reduction of free serum alpha-synuclein levels of up to 96% and demonstrates the pharmacodynamic effects of PRX002.

Alpha-synuclein is a protein found in neurons and is a major component of pathology that characterizes several neurodegenerative disorders including Parkinson`s disease, dementia with Lewy bodies, and multiple system atrophy, which collectively are termed synucleinopathies.

PRX002, the focus of a worldwide collaboration between PRTA and Roche, was safe and well-tolerated, meeting the primary objective of the study.

According to PRTA, this approach may translate into a clinically meaningful delay or reversal of disease progression in patients with Parkinson's disease, a degenerative disorder of the central nervous system that causes tremors, muscle stiffness, slowness of movement, and poor balance and mobility, affecting one in 100 people over age 60.

Shares of PRTA soared more than 40% Thursday in extended-hours trading following the company's announcement.

PRTA is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion.

More about Prothena Corporation plc (PRTA) at http://www.prothena.com.

**

See more here:
Prothena (PRTA) Potential Parkinson's Treatment, Envivio (ENVI) Improved Results, Nike (NKE) ...